EADO 2020 | What is new in melanoma?

Michael Postow, MD, Memorial Sloan Kettering Cancer Center, New York, NY, outlines the latest advances in the field of melanoma, including combination therapy involving nivolumab and ipilimumab in advanced stage IV melanoma, as evaluated in the immuneNED study (NCT02523313), as well as the importance of dosing. Also discussed by Dr Postow is the possibility of combining targeted therapies with immunotherapy, such as the COMBI-i trial (NCT02967692) as well as a Phase III study evaluating vemurafenib and cobimetinib with/without atezolizumab (NCT02908672) which showed an improvement in progression-free survival and led to the approval of the triplet therapy by the US FDA. Finally, Dr Postow highlights novel approaches involving tumor-infiltrating lymphocytes in PD-1 refractory melanoma, as well as evaluating the efficacy of lenvatinib, an anti-angiogenesis agent in melanoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).